<DOC>
	<DOCNO>NCT02420782</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability pharmacokinetics ( PK ) pharmacodynamics ( PD ) single multiple ascend oral dos ASP6282 healthy male female subject . 1 cohort ( elderly ) receive also midazolam dose . This study also explore effect itraconazole ( another drug ) PK ASP6282 , well evaluate safety tolerability ASP6282 alone combination itraconazole healthy male female subject . Also , study evaluate PD PK effect single oral dos ASP6282 pilocarpine-induced salivation pupil diameter healthy nonelderly male female subject .</brief_summary>
	<brief_title>First-in-human : Single Ascending Dose , Food Effect , Drug-drug Interaction , Multiple Ascending Dose , Proof Pharmacology</brief_title>
	<detailed_description>This study consist three part . Part 1 Single Ascending Dose Including Food Effect Drug-drug Interaction ( DDI ) Itraconazole . There washout treatment period 1 2 DDI arm Part 1 ; Part 2 Multiple Ascending Dose ( MAD ) ; Part 3 , treatment period 1 , 2 3 Proof Pharmacology . There washout treatment period</detailed_description>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Pilocarpine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Subject body mass index ( BMI ) range 18.5 30.0 kg/m2 , inclusive . The subject weigh least 50 kg [ screen ] . Female subject must donate ovum start screen throughout clinical study period , 28 day final study drug administration . Male subject female spouse/partners childbearing potential must use highly effective contraception consist 2 form birth control ( 1 must barrier method ) start screen continue throughout clinical study period , 90 day final study drug administration . Male subject must donate sperm start screen throughout clinical study period , 90 day last study drug administration . Subject agree participate another interventional study participate present clinical study , define signing informed consent form completion last study visit . Germany : Female subject must either : Be nonchildbearing potential : 1 . Postmenopausal ( define least 1 year without menses ) prior screening , , 2 . Documented surgically sterile . Or , childbearing potential : 1 . Agree try become pregnant clinical study 90 day final study drug administration , 2 . Must negative serum pregnancy test day 1 , 3 . If heterosexually active , agree consistently use form highly effective birth control combination barrier method start screen continue throughout clinical study period , 90 day final study drug administration . 4 . Or agree stay abstinent , abstinence prefer usual lifestyle subject , start screen continue throughout clinical study period 90 day final study drug administration . Female subject must agree breastfeed start screen throughout clinical study period , 90 day final study drug administration . Female subject must donate ovum start screen throughout clinical study period , 90 day final study drug administration . Female subject pregnant within 6 month prior screen assessment breastfeed within 3 month prior screen . Subject know suspected hypersensitivity ASP6282 , itraconazole ( part 1 DDI ) pilocarpine ( part 3 Proof pharmacology ( PoP ) ) component formulation use . Subject use CYP3A4 metabolize substrate prolong QT interval , e.g. , astemizole , bepridil , cisapride , dofetilide , levacetylmethadol ( levomethadyl ) , mizolastine , pimozide , quinidine , sertindole terfenadine . Subject use follow medication : atorvastatin , lovastatin simvastatin , triazolam , midazolam , ergot alkaloid dihydroergotamine , ergometrine ( ergonovine ) , ergotamine methylergometrine ( methylergonovine ) , eletriptan nisodipine . Subject evidence ventricular dysfunction congestive heart failure history congestive heart failure . Subject clinically significant , cardiorenal disease , asthma and/or disease risk cholinergic agonist . Subject condition eye could affect intake pilocarpine ( e.g. , acute iritis ) ( part 3 PoP ) . Subject liver chemistry test ( Aspartate aminotransferase ( AST ) , Alanine aminotransferase ( ALT ) , alkaline phosphatase ( ALP ) , gamma glutamyl transferase ( GGT ) , Total bilirubin ( TBL ) Upper limit normal ( ULN ) ) . In case , assessment may repeat Day 1 ( part 1 DDI : treatment period 1 ) . Subject clinically significant history allergic condition ( include drug allergy , asthma , eczema anaphylactic reaction , exclude untreated , asymptomatic , seasonal allergy time dose ) . Subject chronic bronchitis and/or chronic obstructive pulmonary disease , know suspected cholelithiasis biliary tract disease , peptic ulceration cognitive psychiatric disturbance , renal hepatic insufficiency , narrowangle glaucoma . Subject has/had febrile illness symptomatic , viral , bacterial ( include upper respiratory infection ) fungal ( noncutaneous ) infection within 1 week prior admission clinical unit Day 1 . Subject clinically significant abnormality follow investigator 's review physical examination , ECG clinical study protocoldefined clinical laboratory test screen day 1 . Subject mean pulse &lt; 40 &gt; 90 bpm ; mean systolic blood pressure ( SBP ) &gt; 140 mmHg ; mean diastolic blood pressure ( DBP ) &gt; 90 mmHg ( vital sign measurement take triplicate subject rest supine position 5 minute ; pulse measure automatically ) admission clinical unit Day 1 . If mean blood pressure exceed limit , 1 additional triplicate take . Subject mean correct QT interval use Fridericia 's formula ( QTcF ) &gt; 430 m ( male subject ) &gt; 450 m ( female subject ) screening . If mean QTcF exceed limit , 1 additional triplicate ECG take screening . Subject use prescribe nonprescribed drug ( include vitamin , natural herbal remedy , e.g. , St. John 's wort ) 2 week prior first study drug administration , except occasional use paracetamol ( 2 g/day ) ( part ) except use contraceptive hormone replacement therapy ( except part 1 DDI ) . Subject history smoking within 6 month prior first study drug administration day 1 . Subject history drinking &gt; 21 unit alcohol/week male subject &gt; 14 unit alcohol/week female subject ( 1 unit = 10 g pure alcohol = 250 mL beer [ 5 % ] 35 mL spirit [ 35 % ] 100 mL wine [ 12 % ] ) within 3 month prior admission clinical unit Day 1 . Subject consume grapefruit/Seville orange , grapefruitcontaining product Seville orangecontaining product within 72 hour prior admission clinical unit Day 1 . Subject use inducer metabolism ( e.g. , barbiturate , rifampin ) within 1 month prior admission clinical unit Day 1 . Subject use drug abuse within 3 month prior admission clinical unit Day 1 . Subject significant blood loss , donate 1 unit ( 500 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day prior admission clinical unit Day 1 . Subject positive serology test hepatitis B surface antigen ( HBsAg ) , hepatitis A virus antibody ( antiHAV ) ( immunoglobulin M [ IgM ] ) , hepatitis C virus antibody ( antiHCV ) , antibodies human immunodeficiency virus type 1 ( HIV1 ) and/or type 2 ( HIV2 ) screening . Subject participate clinical study treat investigational drug within 90 day prior screen . Germany : Subject mean pulse &lt; 50 &gt; 90 bpm ; mean systolic blood pressure ( SBP ) &gt; 140 mmHg ; mean diastolic blood pressure ( DBP ) &gt; 90 mmHg ( vital sign measurement take triplicate subject rest supine position 5 minute ; pulse measure automatically ) admission clinical unit day 1 . ( For elderly subject follow criterion apply : SBP &gt; 160 mmHg DBP &gt; 100 mmHg ) . If mean blood pressure exceed limit , 1 additional triplicate take . Subject mean correct QT interval use Fridericia 's formula ( QTcF ) &gt; 430 m ( male subject ) &gt; 450 m ( female subject ) day 1 . If mean QTcF exceed limit , 1 additional triplicate ECG take day 1 . Subject positive serology test hepatitis B surface antigen ( HBsAg ) , hepatitis B core antibody , hepatitis A virus antibody ( antiHAV ) ( immunoglobulin M [ IgM ] ) , hepatitis C virus antibody ( antiHCV ) , antibodies human immunodeficiency virus type 1 ( HIV1 ) and/or type 2 ( HIV2 ) screening . Subject unable communicate , read understand German , condition , investigator 's opinion , make subject unsuitable clinical study participation . Subject vulnerable subject ( e.g. , subject kept detention ) . Subject know suspected hypersensitivity ASP6282 , itraconazole ( part 1 DDI ) , pilocarpine ( part 3 PoP ) midazolam ( part 2 elderly cohort ) component formulation use . Subject use prescribe nonprescribed drug ( include vitamin , natural herbal remedy , e.g. , St. John 's wort ) 2 week prior first study drug administration , except occasional use paracetamol ( 2 g/day ) ( part ) except use hormone replacement therapy ( except part 1 DDI ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>ASP6282</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Drug-drug interaction</keyword>
	<keyword>Midazolam</keyword>
	<keyword>Safety tolerability</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>Itraconazole</keyword>
</DOC>